Indiana’s life sciences industry is uniquely collaborative and innovative. Much of this is due to a more than 100-year long history of life sciences entrepreneurs and innovation — from Colonel Eli Lilly to Revra DePuy, who started DePuy Orthopedics by crafting the first fiber split; to Bill Cook who innovated catheters and other cardiac devices out of his apartment in the 1960s; to Richard DiMarchi, who founded Marcadia Biotech and a host of other start-up companies and is still creating and discovering.

Countless others have contributed to our robust industry as well. When you look at our extensive, remarkable achievements and their impacts on human heath – insulin and blood glucose meters for diabetes; therapeutics for Hepatitis B, cancer and migraines; monitors to help infants in surgery; medicines and devices for heart; replacement hips; and data for targeted and personalized treatments —  it’s truly astounding.

Once a year we celebrate these achievements by gathering to hear from global thought leaders on topics that are impacting our industry. On September 26, the Indiana Life Sciences Summit will feature speakers on the topic of artificial intelligence’s impact on the life sciences and neuroscience – two areas of critical importance to our industry. Artificial intelligence, machine learning, augmented reality, and data mining are all disrupting the industry with both good and challenging outcomes. How can we harness these potential efficiencies to deliver drugs and devices to the market more quickly, to tailor therapies to the individual, and to ensure more effective and affordable healthcare?

Kiersten Stead, Ph.D., Managing Partner, DCVC Bio, a venture capital firm focused on applying “deep tech” to transform the life sciences; Berk Tas, CEO, Sentiar, a start-up that has created a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, as well as life sciences leaders from Eli Lilly and Company, Covance, Roche Diagnostics, Google Ventures, Regenstrief Institute, Recursion Pharma, and more will be part of the discussion.

Additionally, Central Indiana is actually quite a nexus for neuroscience research and development.  We are seeing an increase in both pre-clinical and clinical stage companies, and industry leaders like Eli Lilly and NICO continue to move their technologies, treatments and therapies forward. Our research universities are engaged in outstanding work. The Scientific Session will focus on the neurosciences with renowned researchers including Bruce Lamb, MD, Director of the Stark Neuroscience Center, and Iliana Apostolova, MD, MSC, FAAN, Indiana University School of Medicine (IUSM), and who was awarded with the largest National Institutes of Health grant ever given to IUSM for her research on early-onset Alzheimer’s Disease. 

Our past has positively impacted medicine and healthcare around the world, and we have an exciting future ahead.

Join us at the conference to both recognize and appreciate our accomplishments, but to also challenge ourselves to bring even more life-changing and life-saving medicines and therapies to realization.

Indiana Life Sciences Summit information and registration are available

Patricia Martin is president and chief executive officer of BioCrossroads.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}